Business
Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay
Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay.
About this update from Zomedica Corp.
[{"type":"text","content":"\r\n\r\n \r\n \r\n Zomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay\r\n \r\n \r\n\r\n\r\nZomedica Expands TRUFORMA(R) Diagnostic Platform with Addition of Feline Use to Cobalamin & Folate Assay\r\n\r\n\r\n\r\n\r\n\r\nFirst and only in-clinic multiplexed Cobalamin & Folate assay now validated for feline patients ANN ARBOR, MI / ACCESS Newswire / September 23, 2025 / Zomedica Corp. (OTCQB:ZOMDF) (\"Zomedica\" or the \"Company\"), a veterinary health company offering innovative point-of-care diagnostic and therapeutic device products for equine and companion animals, today announced the expansion of its TRUFORMA diagnostic platform with the addition of feline testing capability to its cobalamin & folate assay.\r\n Originally launched in early 2024 for canine use, this multiplexed assay-combining two critical tests in one-was the first of its kind to bring both cobalamin and folate testing to the in-clinic setting. Since that time, veterinarians have expressed strong demand to extend this capability to their feline patients.\r\n Highlighting the clinical importance of this expansion, Deborah Greco, DVM, PhD, DACVIM, commented: \"Feline patients with gastrointestinal disease often deteriorate more rapidly than canine patients, making timely and accurate results even more critical. Having access to cobalamin and folate results in under 25 minutes enables veterinarians to initiate or adjust treatment during the same visit-improving both clinical outcomes and the quality of care.\"\r\n \"We launched the canine cobalamin & folate multiplexed assay knowing that non-infectious gastrointestinal conditions such as vomiting and diarrhea are among the most common reasons for veterinary visits,\" noted Michael Mockler, Senior Product Manager for Zomedica. \"Before the introduction of the TRUFORMA platform, veterinarians had no reliable in-clinic option for these tests. Now, they can quickly assess two important biomarkers at the point of care, improving diagnostic efficiency, enhancing workflow, and supporting practice profitability. Expanding this capability to cats represents an important step forward in addressing a critical clinical need.\"\r\n With this new capability, TRUFORMA continues to provide veterinarians with advanced, in-clinic testing solutions that deliv...